Intas Pharma, Henlius receive positive CHMP opinion for Hetronifly in European markets as first line treatment for adult patients with Extensive-Stage Small Cell Lung Cancer
Ahmedabad: Intas Pharmaceuticals Limited has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of HETRONIFLY (Sserplulimab, (approved as HANSIZHUANG in China), in European markets.
Serplulimab, a recombinant humanised anti-PD-1 monoclonal antibody (mAb) injection, is a innovative monoclonal antibody developed by Henlius. It has been granted orphan drug status designation by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of Small Cell Lung Cancer (SCLC).
Serplulimab will be commercialised by Intas through its subsidiary, Accord Healthcare Ltd (Accord), across more than 30 countries in Europe. This positive opinion from CHMP marks another step closer for both Henlius and Intas to provide serplulimab for patients in Europe.
Binish Chudgar, Vice-Chairman and Managing Director of Intas Pharmaceuticals, said, "The CHMP’s positive opinion on sSerplulimab is a pivotal moment in our mission to provide world-class cancer treatments to patients in Europe and across multiple geographies. This strengthens our differentiated oncology portfolio and reinforces Accord’s commitment to alleviating the global cancer burden by ensuring innovative high-quality affordable treatment for those in need."
Paul Tredwell, Executive Vice President of EMENA at Accord, said " Accord are proud to be the leading generic oncology company in Europe, this approval highlights Accords’ continued strategy to build out its speciality business across the region, driving innovation in oncology. I am thrilled with the CHMP's positive opinion. This not only strengthens our current partnership with Henlius but also means serplulimab is on track to become part of the treatment landscape for extensive stage small cell lung cancer patients who currently have limited options and face a poor prognosis. Lung cancer claims more lives than any other cancer and this important medication continues to support our commitment to innovation and growth in an area of high unmet need, as well as our mission to improve access to value-based medicines for patients."
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, stated, “The positive opinion from CHMP signifies a major milestone in our efforts to accelerate the global reach of our products, and further validates Henlius’ patient-centred R&D approach and commitment to global strategy. We look forward to the formal approval of this treatment in Europe, bringing more treatment options and hope to patients there and worldwide.”
According to GLOBOCAN 2022, lung cancer is the most diagnosed and the first mortality cancer around the world. There were more than 2.48 million new cases of lung cancer worldwide in 2022, accounting for 12.4% of all new cancer cases. Small cell lung cancer (SCLC) accounts for 15%–20% of the total number of lung cancer cases and is associated with early metastasis, rapid disease progression, and an extremely poor prognosis.
The positive opinion from CHMP is primarily based on ASTRUM-005, a randomized, double-blind, placebo-controlled international multi-centre clinical study, which evaluated the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with ES-SCLC.
